Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 20/20 | 0.98 |
| ▸ | CSNK2A2 | P19784 | 13/20 | 0.98 |
| ▸ | CSNK2B | P67870 | 9/20 | 0.98 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30466405 | 0.99 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL1928082 | 0.99 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL4973941 | 0.91 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL31061283 | 0.91 | CSNK2A1 (0.84) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL12268708 | 0.90 | CSNK2A1 (0.82) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL10132105 | 0.89 | CSNK2A1 (0.81) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL11928055 | 0.89 | CSNK2A1 (0.81) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL10132108 | 0.88 | CSNK2A1 (0.80) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL10132106 | 0.88 | CSNK2A1 (0.79) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL10132120 | 0.86 | CSNK2A1 (0.77) | CSNK2A1CSNK2A2CSNK2BCSNK2A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20250345206-A1 | APPARATUS AND METHODS FOR OCULAR INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-12350261-B2 | Methods and devices for the treatment of ocular diseases in human subjects | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250186253-A1 | DEVICES AND METHODS FOR ADJUSTING THE INSERTION DEPTH OF A NEEDLE FOR MEDICAMENT DELIVERY | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4566672-A2 | METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS | Clearside Biomedical Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-3554435-B1 | SYSTEMS FOR DELIVERING DRUGS TO RETINAL TISSUE | CLEARSIDE BIOMEDICAL INC (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250152413-A1 | SYSTEMS, DEVICES, AND METHODS FOR NEEDLE-LESS OCULAR INJECTIONS | CLEARSIDE BIOMEDICAL INC (US) | 2025-05-15 | — | — | US | disclosed |
| EP-3721872-B1 | METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS | CLEARSIDE BIOMEDICAL INC (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12201558-B2 | Apparatus and methods for ocular injection | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-12127975-B2 | Devices and methods for adjusting the insertion depth of a needle for medicament delivery | CLEARSIDE BIOMEDICAL, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| CN-110302004-B | Apparatus and method for ocular injection | 科尼尔赛德生物医学公司 | 2023-04-28 | — | — | CN | disclosed |
| US-20230083551-A1 | Formulations for the Suprachoroidal Space of an Eye and Methods | EMORY UNIVERSITY | 2023-03-16 | — | — | US | disclosed |
| US-11596545-B2 | Systems and methods for ocular drug delivery | CLEARSIDE BIOMEDICAL, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-11559428-B2 | Apparatus and methods for ocular injection | CLEARSIDE BIOMEDICAL, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-2887982-B1 | APPARATUS FOR DRUG DELIVERY USING MICRONEEDLES | CLEARSIDE BIOMEDICAL INC (US) | 2022-11-23 | — | — | EP | disclosed |
| US-11504431-B2 | Formulations for the suprachoroidal space of an eye and methods | EMORY UNIVERSITY (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220280341-A1 | APPARATUS AND METHODS FOR DRUG DELIVERY USING MICRONEEDLES | CLEARSIDE ROYALTY LLC | 2022-09-08 | — | — | US | disclosed |
| US-20220280386-A1 | METHODS AND APPARATUS FOR EXTRACTING FLUID FROM CONTAINER | CLEARSIDE BIOMEDICAL, INC. | 2022-09-08 | — | — | US | disclosed |
| WO-2022076938-A1 | APPARATUS AND METHODS OF RETINAL INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-110177527-B | Device and method for adjusting insertion depth of needle for medicament delivery | 科尼尔赛德生物医学公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | CSNK2A1 2259/4885CSNK2A2 2339/4885CSNK2B 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.